For decades, living with hemophilia has meant living with needles. Regular intravenous infusions of clotting factors—sometimes several times a week—have been the backbone of treatment, helping patients prevent or control potentially life-threatening bleeding. While these therapies have dramatically improved life expectancy and quality of life, they do not cure the disease. Today, however, a new frontier is emerging: gene therapy. This breakthrough approach is reshaping the future of hemophilia care, offering hope for long-term, possibly one-time treatment solutions.

Hemophilia is a genetic bleeding disorder caused by a deficiency of clotting proteins—factor VIII in hemophilia A and factor IX in hemophilia B. Without these proteins, even minor injuries can lead to prolonged bleeding, joint damage, and serious complications.

The standard treatment has long been factor replacement therapy, where patients receive synthetic or plasma-derived clotting factors through intravenous injections. These treatments are highly effective in preventing bleeds and enabling relatively normal lives. However, they come with significant challenges.

Patients often require injections as frequently as every day or every few days, especially in severe cases. This creates a lifelong dependency on medical care, increases treatment costs, and can be physically and emotionally taxing—particularly for children and caregivers. Moreover, the infused clotting factors are gradually broken down by the body, meaning their effects are temporary and must be replenished continuously.

Even with advances like extended half-life products and non-factor therapies, the fundamental limitation remains: these treatments manage the condition but do not address its genetic root.

Gene therapy: treating the cause, not just symptoms

Gene therapy represents a paradigm shift. Instead of repeatedly supplying the missing clotting factor, it aims to enable the body to produce it on its own.

In hemophilia, gene therapy typically uses a harmless viral vector—most commonly an adeno-associated virus (AAV)—to deliver a functional copy of the defective gene into the patient’s liver cells. Once inside, these cells begin producing the missing clotting factor, potentially restoring the body’s natural ability to form clots.

This approach is fundamentally different from traditional therapy. It targets the disease at its genetic origin, offering the possibility of long-lasting or even one-time treatment. In fact, gene therapy has been described as the first strategy that could free patients from the burden of repeated injections.

Clinical trials have shown promising results. Patients receiving gene therapy have demonstrated sustained production of clotting factors, significantly reducing bleeding episodes and, in some cases, eliminating the need for regular prophylactic treatment.

Benefits of therapy

The potential advantages of gene therapy go far beyond reducing injections. First, it offers greater treatment independence. Patients may no longer need to plan their lives around infusion schedules, travel with medical supplies, or worry about missing doses. Second, it could reduce long-term complications. By maintaining more stable levels of clotting factors, gene therapy may help prevent joint damage and other chronic issues caused by repeated bleeding. Third, there is a strong economic argument. While gene therapy is currently expensive upfront, it could reduce lifetime healthcare costs by eliminating the need for continuous treatment, hospital visits, and management of complications.

Challenges of therapy

Despite its promise, gene therapy is not without limitations. One major concern is durability. While studies show sustained factor production for several years, it is still unclear how long the effects will last over decades. Another challenge is eligibility. Not all patients can receive gene therapy. Pre-existing immunity to the viral vector, underlying liver disease, or other medical conditions may exclude some individuals. And there are also safety considerations. Some patients experience immune reactions or temporary liver inflammation following treatment. Additionally, because the therapy typically cannot be repeated using the same vector, patients may have only one opportunity to receive it. Cost and access remain significant barriers as well. The high upfront price of gene therapy limits availability, particularly in low- and middle-income countries where access to even standard treatments can be inconsistent.

Way Ahead

The future of hemophilia care will likely be defined by a combination of therapies rather than a single solution. While gene therapy holds transformative potential, traditional treatments and newer non-factor therapies will continue to play important roles—especially for patients who are not eligible for gene therapy.

Ongoing research is focused on improving gene delivery methods, enhancing durability, and developing gene-editing technologies that could offer more permanent solutions. Scientists are also exploring ways to make therapies safer, more accessible, and applicable to a broader patient population.

Conclusion

The journey from injections to gene therapy marks one of the most significant evolutions in hemophilia care. What was once a lifelong regimen of frequent infusions is gradually giving way to innovative treatments that aim to correct the disease at its source.

While challenges remain, the progress made so far signals a future where hemophilia may no longer dictate the rhythm of a patient’s life. Instead of managing symptoms day by day, patients may soon experience sustained relief—perhaps even functional cures—through a single transformative intervention.

In this shifting landscape, gene therapy is not just a new treatment; it is a glimpse into a future where chronic genetic diseases can be fundamentally redefined.

About the author- Dr. Kaushik Paul, Consultant, Haematology (Fortis Anandapur)